UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that the Centers for ...

UroGen Pharma (URGN) announced that the Centers for Medicare and Medicaid Services, CMS, has assigned a permanent Healthcare Common Procedure ...

UroGen Pharma shows strong growth with RTGel technology, FDA approvals for JELMYTO and ZUSDURI, and accelerating 2026 revenue outlook. See why URGN stock is a buy.

This biotech could be high risk, high reward picks according to Bell Potter. Mesoblast shares climb 9% following a positive broker note from Bell Potter, highlighting the approval of a J-Code for its ...

Opening South County Hospital's spreadsheet, the hernia code is easier to find, as there's only one entry instead of an entry ...

I’ve never been more alarmed about the state of our democracy. The U.S. is sliding toward authoritarianism faster than ever, while corporate media turns a blind eye. That’s why Common Dreams exists—to ...

Nearly two decades after the first statewide interoperability plan, the need for governance, standardized procedures, and ...

Ambulatory surgery centers (ASCs) are increasingly important to health systems’ long-term growth strategies. ASC partnerships or purchases can increase a health system’s revenue and capacity and ...

The Centers for Medicare & Medicaid Services (CMS) has released the final National Coverage Determination (NCD) on renal de ...

Erratum: Identifying Patients With Low Relapse Rate Despite High-Risk Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Early Breast Cancer: Development and Validation of a ...

Data is not available at this time. Insider Trading information for NDAQ is derived from Forms 3 and 4 filings filed with the U.S. Securities and Exchange Commission (SEC). Please Note:An FPI is ...

The pass rate for the first level of the chartered financial analyst exam fell to 43% for humans even as artificial-intelligence models have advanced to the point they can ace the final and hardest ...